Repare Secures $40M Milestone Payment from Roche in Clinical Trial Achievement

Repare Therapeutics Inc., a leader in precision oncology, has achieved a significant milestone through its collaboration with Roche for developing and commercializing camonsertib. The company has received a $40 million milestone payment from Roche following the administration of camonsertib to the first patient in Roche's TAPISTRY Phase 2 clinical trial. This trial is global and multicenter, focusing on evaluating the safety and effectiveness of targeted therapies or immunotherapies in patients with advanced solid tumors that exhibit specific genomic alterations.

Additionally, in October, Roche introduced the first patient in a camonsertib-based arm of its Phase 1b/2 clinical trial, which aims to explore various immunotherapy combinations in patients with metastatic non-small cell lung cancer (Morpheus Lung). Both the TAPISTRY and MORPHEUS trials are ongoing, actively enrolling patients to explore the efficacy of camonsertib in diverse cancer treatments. Furthermore, Repare continues tumor-specific expansions in its ATTACC trial, in partnership with Roche, to support future clinical developments for camonsertib and PARP inhibitor combinations.

According to Lloyd M. Segal, President and CEO of Repare, this milestone underscores Roche’s commitment to the global development of camonsertib. It highlights Roche’s efforts to explore the drug’s potential across various tumor types and genetic modifications, aiming to maximize patient benefit.

Under the terms of the collaboration, Repare received a $125 million upfront payment in July 2022, along with $13.6 million in additional payments. They are eligible for up to $1.2 billion in potential milestone payments, along with royalties on global net sales. The collaboration also allows Repare the option to participate in a 50/50 U.S. co-development and profit-sharing arrangement, including possible U.S. co-promotion if regulatory approval is granted. Should Repare opt-in, they remain eligible for certain milestone payments alongside full ex-U.S. royalties.

Repare's platform, SNIPRx®, utilizes genome-wide CRISPR-based screening to identify synthetic lethal gene pairs and suitable patient profiles for tailored therapy based on tumor genetics. This technology facilitates the development of precision medicine, targeting tumors that are likely to respond to resultant therapies.

Repare Therapeutics is a clinical-stage company, known for its synthetic lethality strategy in discovering and developing innovative cancer treatments. Their SNIPRx® platform powers the systematic development of targeted therapies addressing genomic instability, notably DNA damage repair. The company's pipeline comprises several active and preclinical programs, including lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 trials, and camonsertib (RP-3500 or RG6526), an ATR inhibitor currently in Phase 1/2 development, partnered with Roche. Other preclinical programs include RP-1664, a PLK4 inhibitor, and RP-3467, a Polθ inhibitor, among undisclosed projects.